Nrx Pharmaceuticals Stock Beneish M Score

NRXP Stock  USD 2.07  0.11  5.05%   
This module uses fundamental data of NRX Pharmaceuticals to approximate the value of its Beneish M Score. NRX Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out NRX Pharmaceuticals Piotroski F Score and NRX Pharmaceuticals Altman Z Score analysis.
To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.
  
At this time, NRX Pharmaceuticals' Net Debt is relatively stable compared to the past year. As of 03/21/2025, Short Term Debt is likely to grow to about 11.1 M, while Short and Long Term Debt is likely to drop slightly above 1.5 M. At this time, NRX Pharmaceuticals' Days Of Payables Outstanding is relatively stable compared to the past year.
At this time, it appears that NRX Pharmaceuticals is an unlikely manipulator. The earnings manipulation may begin if NRX Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by NRX Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of NRX Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-16.29
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

N/A

Focus
Asset Quality

N/A

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

N/A

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

0.84

Focus

NRX Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if NRX Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Assets3.5 M3.7 M
Notably Down
Slightly volatile
Total Current Assets3.1 M3.3 M
Notably Down
Slightly volatile
Non Current Assets Total331.6 K349 K
Notably Down
Slightly volatile
Depreciation And Amortization4.3 K4.5 K
Notably Down
Slightly volatile
Selling General Administrative19.6 M13.5 M
Way Up
Slightly volatile
Total Current Liabilities16.1 M21.9 M
Way Down
Slightly volatile
Short Term Debt11.1 M10.5 M
Sufficiently Up
Slightly volatile
Long Term Debt2.9 M5.8 M
Way Down
Slightly volatile
Short Term Investments5.1 M5.4 M
Notably Down
Slightly volatile

NRX Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between NRX Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards NRX Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find NRX Pharmaceuticals' degree of accounting gimmicks and manipulations.

About NRX Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

4,275

At this time, NRX Pharmaceuticals' Depreciation And Amortization is relatively stable compared to the past year.

NRX Pharmaceuticals Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as NRX Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
202020212022202320242025 (projected)
Total Assets2.9M32.7M25.8M7.3M3.7M3.5M
Total Current Assets2.9M32.7M25.8M6.9M3.3M3.1M
Non Current Assets Total11K15K21K431K349K331.6K
Selling General Administrative11.4M74.9M27.4M14.2M13.5M19.6M
Total Current Liabilities46.2M11.9M16.6M19.0M21.9M16.1M
Non Current Liabilities Total548K4.2M1.8M0.05.0M5.3M
Net Debt(1.1M)(27.1M)(9.5M)4.6M5.1M5.4M
Long Term Debt2.0M2.7M2.8M5.0M5.8M2.9M
Operating Income(51.4M)(115.8M)(44.4M)(27.6M)(18.5M)(19.4M)
Total Cash From Operating Activities(2.3M)(37.7M)(39.8M)(21.7M)(10.6M)(11.2M)

NRX Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NRX Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NRX Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

About NRX Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NRX Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRX Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRX Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.